Insight Molecular Diagnostics Inc. Income Statement
IMDX|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Insight Molecular Diagnostics Inc. reported $2M in revenue and $61M in net loss for FY2025. Revenue has grown at a 9.1% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | $1.5M | $958.0K | $2.2M | $1.2M | $1.2M |
| Cost of Revenue | $1.1M | $1.0M | $880.0K | $697.0K | $1.9M | $1.9M |
| Gross Profit | $740.0K | $413.0K | -$18.0K | $1.4M | -$639.0K | - |
| SG&A Expense | $10.2M | $11.2M | $21.9M | $22.3M | $16.8M | $13.3M |
| R&D Expense | $9.8M | $9.3M | $7.3M | $5.0M | $9.8M | $6.8M |
| Operating Income | -$61.0M | -$25.1M | -$18.0M | -$53.7M | -$29.7M | -$22.2M |
| Interest Expense | -$84.0K | -$52.0K | -$83.0K | -$209.0K | -$252.0K | $299.0K |
| Income Tax | $0 | $0 | - | -$9.3M | -$1.3M | -$1.3M |
| Net Income | -$60.7M | -$27.8M | -$72.9M | -$64.1M | -$29.9M | -$22.4M |
| EPS (Basic) | -$4.66 | -$3.75 | -$13.25 | -$0.72 | - | - |
| EPS (Diluted) | -$4.66 | -$3.75 | -$13.25 | - | -$0.46 | -$0.44 |
| Shares Outstanding | 17.5M | 8.3M | 5.9M | 92.2M | 69.1M | 57.0M |
| Gross Margin | 39.3% | 27.5% | -1.9% | 64.6% | -52.5% | - |
| Operating Margin | -3245.1% | -1672.4% | -1878.6% | -2444.3% | -2443.3% | -1828.9% |
| Profit Margin | -3225.0% | -1848.4% | -7609.8% | -2916.2% | -2461.5% | -1844.2% |